Cancer incidence and mortality after heart transplantation – A population-based national cohort study

Figures & data

Table 1. Characteristics of the cohort.

	n	%
Total	479	100
Male	381	79.5
Age at transplantation
<40	95	19.8
40–49	110	23.0
50–59	186	38.8
>60	88	18.4
Year of transplantation
1985–2002	286	59.7
2003–2010	121	25.3
2011–2014	72	15.0
Diagnosis
DCMP	237	49.5
CAD	152	31.7
Other CMP	19	4.0
Giant cell myocarditis	14	2.9
Sarcoidosis	14	2.9
Congenital heart disease	19	4.0
Valvular disease	15	3.1
Infectious myocarditis	6	1.3
Amyloidosis	3	0.6
Cancer before transplantation	21	4.4
Lymphoma or acute leukaemia	8	1.7
Solid cancer	13	2.7

DCMP: dilated cardiomyopathy; CAD: coronary artery disease; CMP: cardiomyopathy.

Table 2. All cancers with their corresponding SIRs.

Cancer site	OBS	EXP	SIR	95% CI	p-value
All sites	267	44.9	6.0	5.3–6.7	<.001
All sites excluding NMSC	128	35.9	3.6	3.0–4.2	<.001
Skin, squamous cell carcinoma	56	1.1	51.9	39.2–67.4	<.001
Skin, basal cell carcinoma	83	7.9	10.5	8.4–13.0	<.001
Skin, melanoma	5	1.3	3.8	1.2–8.8	<.01
Kaposi’s sarcoma	1	0	365.0	9.2–2033	<.01
Non-Hodgkin lymphoma	36	1.4	25.7	18.0–35.6	<.001
Hodgkin lymphoma	2	0.1	15.2	1.8–54.8	<.001
Myelodysplastic syndromes	1	0.1	13.9	0.3–77.4	.11
Acute myeloid leukemia	1	0.7	1.4	0.0–8.0	1.00
Chronic lymphatic leukemia	3	0.8	3.9	0.8–11.4	.09
Myeloma	0	0.4	0	–	–
Lip	7	0.2	47.4	19.1–97.7	<.001
Tongue	4	0.2	26.3	7.2–67.4	<.001
Salivary glands	1	0.1	12.6	0.3–70.3	.14
Other oral	1	0.2	4.9	0.1–27.1	.52
Nose and sinuses	1	0.1	16.9	0.4–94.2	.07
Lungs and trachea	17	4.4	3.9	2.3–6.3	<.001
Pharynx	1	0.3	3.5	0.1–19.3	.69
Kidney	12	1.3	9.5	4.8–16.1	<.001
Bladder and urinary tract	6	1.7	3.5	1.3–7.5	<.01
Prostate	15	10.3	1.5	0.8–2.4	.20
Colon	7	1.9	3.7	1.5–7.6	<.01
Esophagus	1	0.5	2.2	0.1–12.1	.96
Stomach	2	1.0	2.0	0.2–7.3	.61
Liver	1	0.6	1.7	0.0–9.2	.89
Pancreas	1	1.3	0.8	0.0–4.4	.83
Rectum and rectosigmoid	0	1.5	0	–	–
Breast	0	1.7	0	–	–
Gynecological organs	0	0.6	0	–	–
Brain, central nervous system	1	1.0	1.0	0.0–5.5	.63
Ill -defined or unknown	1	0.6	1.6	0.0–9.1	.25

CI: confidence interval; EXP: expected; NMSC: non-melanoma skin cancer; OBS: observed; SIR: standardized incidence ratio.

Figure 1. Standardized incidence ratio (SIR) for overall cancer with 95% confidence intervals as a function of time since heart transplantation (HTx).